Related Experiment Video
Updated: Dec 5, 2025
05:44
Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
2.0K
Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in
K Arnold Chan1,2, Yu-Chun Hsieh3, Shu-Feng Hsieh3
1Health Data Research Center, National Taiwan University, 33, Linsen South Road, Suite 526, Taipei, Taiwan. kachan@ntu.edu.tw.
Drugs - Real World Outcomes
|October 17, 2020
Summary
The introduction of extended-release pramipexole in Taiwan led to higher daily doses and improved medication adherence for Parkinson's disease patients compared to the immediate-release form.
Area of Science:
- Pharmacology
- Neurology
- Health Services Research
Background:
- Evaluating real-world drug impacts necessitates population-based health data.
- Pramipexole is a dopamine agonist used for Parkinson's disease.
Purpose of the Study:
- To assess changes in pramipexole utilization in Taiwan post-introduction of its extended-release (ER) formulation.
- Compare drug use patterns between immediate-release (IR) and ER pramipexole.
Main Methods:
- Utilized Taiwan's National Health Insurance claims data.
- Identified Parkinson's disease patients prescribed pramipexole.
- Analyzed drug use patterns, levodopa equivalent dose per day (LEDD), and 1-year adherence (medication possession ratio, MPR) from 2009-2017.
Main Results:
- Pramipexole ER prescriptions were associated with over double the LEDD compared to pramipexole IR.
- One-year MPR for pramipexole ER initiators exceeded 73% (2012-2016).
- One-year MPR for pramipexole IR initiators was below 65% (2010-2011).
Conclusions:
- Pramipexole ER introduction in Taiwan increased prescribed LEDD.
- Patients initiated on pramipexole ER demonstrated superior medication adherence compared to those on pramipexole IR.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
491
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
491
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
101
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
101
01:26FDA Approved Drugs: Changes to Approved Drugs
106
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
106
01:19Pharmacovigilance
1.5K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.5K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
107
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
107
01:29Therapeutic Drug Monitoring: Affecting Factors
102
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
102